PMID- 24021598
OWN - NLM
STAT- MEDLINE
DCOM- 20140902
LR  - 20220330
IS  - 1437-4331 (Electronic)
IS  - 1434-6621 (Linking)
VI  - 52
IP  - 2
DP  - 2014 Feb
TI  - Enrichment and enumeration of circulating tumor cells by efficient depletion of 
      leukocyte fractions.
PG  - 243-51
LID - 10.1515/cclm-2013-0558 [doi]
AB  - BACKGROUND: Enumeration and characterization of circulating tumor cells (CTCs) 
      can provide information on patient prognosis and treatment efficacy. However, 
      CTCs are rare, making their isolation a major technological challenge. We 
      developed a technique for enrichment, and subsequent characterization of CTCs 
      based on efficient depletion of human leukocytes. METHODS: The technique 
      (CanPatrolTM CTC enrichment) we developed is based on red blood cell lysis to 
      remove erythrocytes, followed by depletion of CD45+ leukocytes using a magnetic 
      bead separation method, and subsequent isolation of CTCs by virtue of their 
      larger size, compared with leukocytes. We also demonstrated that fluorescence in 
      situ hybridization (FISH) and genetic abnormalities analysis could be performed 
      on the isolated CTCs. RESULTS: The spiking experiments showed that the average 
      efficacy of leukocytes depletion was 99.98% and the average tumor cells recovery 
      was not lower than 80%. FISH could be used to perform ALK gene rearrangement 
      analysis on the collected NCI-H2228 cells, and EGFR Exon 19 deletion was detected 
      by PCR-based analysis in isolated HCC827 cells. The in vivo feasibility of this 
      technique had been demonstrated in patients with non-small cell lung cancer, 
      breast, colon, and esophageal cancers. CTCs were detected in 13 of 59 blood 
      samples. Tumor microemboli was also detected in three breast cancer samples. 
      CONCLUSIONS: The technique we developed allowed isolation and characterization of 
      circulating epithelial tumor cells that do not express classical epithelial 
      antigens. This potentially leads to a more accurate enumeration of the number of 
      CTCs and is suitable for application to a broad range of cancers.
FAU - Wu, Shiyang
AU  - Wu S
FAU - Liu, Zhiming
AU  - Liu Z
FAU - Liu, Suyan
AU  - Liu S
FAU - Lin, Li
AU  - Lin L
FAU - Yang, Weiwei
AU  - Yang W
FAU - Xu, Jiasen
AU  - Xu J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
EIN - Clin Chem Lab Med. 2015 Feb;53(2):337
EIN - Clin Chem Lab Med. 2015 Feb;53(2):337. PMID: 25568985
MH  - Anaplastic Lymphoma Kinase
MH  - Cell Line, Tumor
MH  - Cell Size
MH  - DNA/analysis
MH  - DNA Mutational Analysis
MH  - ErbB Receptors/genetics/metabolism
MH  - Erythrocytes/cytology/metabolism
MH  - Female
MH  - Hemolysis
MH  - Hep G2 Cells
MH  - Humans
MH  - *Immunomagnetic Separation
MH  - Leukocyte Common Antigens/immunology/metabolism
MH  - Leukocytes/*cytology/metabolism
MH  - MCF-7 Cells
MH  - Male
MH  - Mutation
MH  - Neoplasm Staging
MH  - Neoplasms/immunology/metabolism/pathology
MH  - Neoplastic Cells, Circulating/*metabolism
MH  - Receptor Protein-Tyrosine Kinases/genetics/metabolism
EDAT- 2013/09/12 06:00
MHDA- 2014/09/03 06:00
CRDT- 2013/09/12 06:00
PHST- 2013/05/27 00:00 [received]
PHST- 2013/08/03 00:00 [accepted]
PHST- 2013/09/12 06:00 [entrez]
PHST- 2013/09/12 06:00 [pubmed]
PHST- 2014/09/03 06:00 [medline]
AID - /j/cclm.ahead-of-print/cclm-2013-0558/cclm-2013-0558.xml [pii]
AID - 10.1515/cclm-2013-0558 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2014 Feb;52(2):243-51. doi: 10.1515/cclm-2013-0558.